About Omass
Omass is a company based in Oxford (United Kingdom) founded in 2016 by Jonathan Hopper and Idlir Liko was acquired by Syncona in November 2018. Omass has raised $19.32 million across 2 funding rounds from investors including Syncona and Oxford Science Enterprises. The company has 39 employees as of December 31, 2021. Omass operates in a competitive market with competitors including Evelo Biosciences, PathogenDX, Phylos Bioscience, AFYREN and Crawford Scientific, among others.
- Headquarter Oxford, United Kingdom
- Employees 39 as on 31 Dec, 2021
- Founders Jonathan Hopper, Idlir Liko
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Omass Therapeutics Limited
- Date of Incorporation 26 Feb, 2016
- Jurisdiction OXFORD, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Omass
Omass has successfully raised a total of $19.32M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17.9 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Omass
Omass has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Syncona and Oxford Science Enterprises.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are managed via private equity by Syncona.
|
Locked | Locked | Locked | |
|
Investment management services for science ventures are provided in Oxford.
|
Locked | Locked | Locked |
Investor details for Omass
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Omass
Investment portfolio details for Omass
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Omass
Detailed financials for Omass
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Omass Comparisons
Peer comparison for Omass
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Omass
Omass operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, PathogenDX, Phylos Bioscience, AFYREN and Crawford Scientific, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of DNA-based pathogen testing kits
|
|
| Locked | Locked | Locked |
Developer of cannabis breeding tools for agriculture & other health purposes
|
|
| Locked | Locked | Locked |
Analytical services are provided for microbiology, chemistry, and bioprocesses sectors.
|
|
| Locked | Locked | Locked |
Service provider in analytical testing
|
Detailed competitors of Omass
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Omass
Complete news archive for Omass
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omass
Omass was founded in 2016.
Omass is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Omass is a funded company, having raised a total of $19.32M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Omass is 39.
Omass was established in 2016 in Oxford, United Kingdom, as a service provider in the pharmaceutical and research sectors. Native mass spectrometry is applied by the company to characterize intact protein assemblies, supporting drug discovery processes. Solutions are delivered through this specialized platform to clients in these industries, with operations focused on analytical services for protein-based research and development.
Omass's top competitors include PathogenDX, AFYREN and Perfectus Biomed.
Omass has 2 investors. Key investors include Syncona, and Oxford Science Enterprises.